Clinical trials: Etoposide, completed
Lung Cancer
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00433498
- Testing
- carboplatin, cisplatin, etoposide phosphate
- Where
- 86 sites in United Kingdom
- Volunteers
- 846 people
- Sponsor
- University College, London
Multiple Myeloma
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
The purpose of this phase II study is to assess the toxicity and efficacy of sequentially administered high dose chemotherapy followed by autologous stem cell rescue in the treatment of multiple myeloma.
- Trial name
- NCT00586014
- Testing
- High-Dose Sequential Chemotherapy followed by ASCT
- Volunteers
- 91 people
- Sponsor
- Duke University
Lymphoma
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00568815
- Testing
- Rituximab combined with ESHAP
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fudan University
T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous injection.
- Conditions
- T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
- Trial name
- NCT01445535
- Testing
- Rituximab, Etoposide, Siplizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Acute,Leukemia, Lymphoid
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
In this single-center, open-label, no control,prospective clinical trial, a total of 30 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients will be enrolled.
- Trial name
- NCT02523976
- Testing
- Dasatinib, prednisone, cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Adult Acute Lymphocytic Leukemia
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in CD20 positive standard risk patients.
- Trial name
- NCT00199004
- Testing
- Cyclophosphamide, Dexamethasone / Prednisolone, Vincristine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00004176
- Testing
- amifostine trihydrate, cisplatin, etoposide
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Ovarian Tumors
French Observatory of Rare Malignant Tumors of the Ovary
To take charge of the treatment in rare adult ovarian tumors with an homogenous manner (germinal and sexual cords tumors), at different stages of the disease.
- Trial name
- NCT01304043
- Testing
- chemotherapies protocols
- Where
- France
- Volunteers
- 204 people
- Sponsor
- ARCAGY/ GINECO GROUP
Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Background: Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous…
- Trial name
- NCT01030900
- Testing
- Campath, Rituximab, EPOCH
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00007852
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Nebraska
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Leukemia
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00070174
- Testing
- asparaginase, busulfan, cyclophosphamide
- Where
- 148 sites in United States, Australia and 3 more
- Volunteers
- 350 people
- Sponsor
- Children's Oncology Group